Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. - Wikidata - wikimedia - TriplyDB

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33368803

about

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.Bortezomib: the evidence of its clinical impact in multiple myeloma.A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.p53 abnormalities and potential therapeutic targeting in multiple myeloma.Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.Complete atrioventricular block secondary to bortezomib use in multiple myeloma.Proteasome inhibitors in the treatment of multiple myeloma The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response.Cardiotoxicity of molecularly targeted agents Bortezomib for multiple myeloma.Proteasome inhibitor bortezomib for the treatment of multiple myeloma.A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.Bortezomib in mantle cell lymphoma.Treatment of relapsed and refractory myeloma.Bortezomib-induced Severe Congestive Heart Failure.Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.Antineoplastic drug-induced bradyarrhythmias.Cancer chemotherapy and cardiac arrhythmias: a review.Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model.The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats.Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.Abstracts Quick response to bortezomib plus dexamethasone in a patient with AL amyloidosis in first relapse

P2860

Q33386405-9BCC6593-427B-492A-AE72-7FBBF8073D14 Q33400724-A1FE68D8-BFA7-400F-ADE4-F4ED92DEF360 Q33405134-ABB2FCCC-2C9E-4CF0-909B-76256049696F Q33852683-C1463814-3BCC-42A6-A8EE-AD056ADDC9A0 Q34353682-7ED3D8C6-C233-4143-B365-E210502A5A59 Q34474586-DD6F90ED-509D-4F0B-9583-5964449CBFBC Q34611676-8A7518A3-7536-42B4-A751-B1DECF6756E3 Q35444159-3483056A-10C0-4528-94E1-C2B3B0EF64FE Q35756951-66E49E7C-74AE-4B58-962C-3AFE208C020A Q35878459-043520B1-7AC1-4E4B-BFE2-8466BE358AB4 Q36521862-062DF884-5C15-45BF-83FF-5AE2DE238531 Q36523911-24ED746D-7C38-42C3-BE07-CE535ED57C23 Q37052843-06A2E7F2-EA19-4666-AAFD-345EC5CF732A Q37136989-942CC168-EF3E-4E32-A94D-E2D5DBAFB0A8 Q37209929-384665C6-2C4E-464A-B5CE-8EE46190F416 Q37711394-916379A3-355B-4B2E-A773-AB15EB856FB5 Q37760210-80FC5265-D314-43F5-9920-67FB79C17F33 Q38025714-259AA250-3220-481A-BB5B-6A6664B57399 Q38313870-31857E77-E76D-49D8-B8ED-77B4DB590B55 Q42496084-AEA3576F-983F-4F88-848F-3349A2A43FE5 Q42932963-1F92BC66-1730-4C4B-930F-6F341B93E381 Q46577984-49229472-F0CB-4BA7-9CAF-31076157D19D Q57259399-F4FF6859-13EA-4AB3-85EF-430B4EE93772 Q58262875-EACD0163-4D55-4FBB-BDE8-4213C06E54C8

P2860

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33368803

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

@ast

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

@en

type

label

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

@ast

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

@en

prefLabel

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

@ast

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

@en

P1433

Q33368803-21876196-910C-4EE4-802D-7DEB7C2D299B

P1476

Q33368803-00808B02-0DC1-4390-8323-FADEA111753B

P2093

Q33368803-113BDF56-4549-453D-B21E-6DA69AAB5DD7

Q33368803-13302C0A-C3A1-43CD-9ECE-D1BEDE600F29

Q33368803-268EA425-FF60-41F5-9D6E-9225E1F84A18

Q33368803-2DCB9B50-1AEE-49E1-B842-23FC9BB98B47

Q33368803-2F2E0061-0F4C-4C74-96BD-1E374345EB73

Q33368803-475BC688-EE4D-48AC-BC26-CF3AA0B54CC1

Q33368803-49DF4E6E-4198-4388-9F16-129FDF5A1B1D

Q33368803-4E3D276C-92C9-405E-8534-EDEC70F9182C

Q33368803-95288027-7CCA-4954-AFAC-BEE56CB4B79A

Q33368803-B355A092-6CA0-4582-8D28-6A496AED4733

P304

Q33368803-16E1CDFB-203D-4CFA-96BD-4185C6A298FA

P31

Q33368803-E37471C1-2DB0-4CF7-A0F8-41700792298F

P356

Q33368803-1F375054-B1F1-4A13-B431-3F93A7B6358D

P407

Q33368803-E7832395-B46D-49BA-9FC6-3D9B736A02B4

P433

Q33368803-6A8E44E5-8103-4FD0-B757-6FC80B7ED967

P478

Q33368803-A55ACF90-DE03-4746-ACAE-401A8B471F68

P50

Q33368803-043D4B75-E3C0-446F-A2E3-0AF89E431D3E

Q33368803-0F639422-CDA4-4376-A76B-EA9CB5772108

Q33368803-333155D8-66D2-469C-AE3C-E20822140496

Q33368803-8186E1E7-7459-43F6-91B8-CCF78F2FAC65

Q33368803-C4A3FE93-6543-4F8A-981D-09791A3A6AE2

P577

Q33368803-13ED096F-B97D-4EAC-A36E-D4896B4FBFD3

P5875

Q33368803-13BF1074-D5A1-4B34-8E8E-0DD134920563

P698

Q33368803-A0D31E02-6AB5-436D-8663-36B64ADF0AC5

P356

P1433

P1476

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

@en

P2093

David Irwin

http://www.w3.org/2001/XMLSchema#string

David P Schenkein

http://www.w3.org/2001/XMLSchema#string

David T Siegel

http://www.w3.org/2001/XMLSchema#string

Dixie L Esseltine

http://www.w3.org/2001/XMLSchema#string

Elizabeth Trehu

http://www.w3.org/2001/XMLSchema#string

Gordon Srkalovic

http://www.w3.org/2001/XMLSchema#string

James R Berenson

http://www.w3.org/2001/XMLSchema#string

Melissa Alsina

http://www.w3.org/2001/XMLSchema#string

Raymond Alexanian

http://www.w3.org/2001/XMLSchema#string

Seema Singhal

http://www.w3.org/2001/XMLSchema#string

P304

2141-2148

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.21427

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

S. Vincent Rajkumar

Kenneth C Anderson

Paul G Richardson

Ruben Niesvizky

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7559712

http://www.w3.org/2001/XMLSchema#string

P698

16206291

http://www.w3.org/2001/XMLSchema#string